Evidence map›Paper›PMID 21775973›Full record

Trial reportKidney international2011

The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.

Michael V Rocco, Robert S Lockridge, Gerald J Beck, Paul W Eggers, Jennifer J Gassman, Tom Greene, Brett Larive, Christopher T Chan, Glenn M Chertow, Michael Copland and 100 more

2 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Kidney international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 171 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 16 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04087213 nacompletednot on this mapstarted 2019, after this paper: background citation

Clinical Evaluation of the HemoCare™ Hemodialysis System for Home Nocturnal Hemodialysis

TypeinterventionalSponsorDeka Research and DevelopmentRan2019 to 2023Enrolled36ConditionsEnd-Stage Renal DiseaseArmsHemoCare™ Hemodialysis System
NCT04198012 nacompletednot on this mapstarted 2019, after this paper: background citation

An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System for Home Hemodialysis Prior to Market Authorization

TypeinterventionalSponsorDeka Research and DevelopmentRan2019 to 2024Enrolled25ConditionsEnd Stage Renal DiseaseArmsHemoCare™ Hemodialysis System
3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 16 syntheses or guidelines pooled it.

  1. Guideline
  2. Low dialysate sodium levels for chronic haemodialysis.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Interventions for fatigue in people with kidney failure requiring dialysis.The Cochrane database of systematic reviews · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Low dialysate sodium levels for chronic haemodialysis.The Cochrane database of systematic reviews · 2019
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Home versus in-centre haemodialysis for end-stage kidney disease.The Cochrane database of systematic reviews · 2014
    Pooled it
  16. Effect of frequent or extended hemodialysis on cardiovascular parameters: a meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2012
    Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

110 authors.

Michael V RoccoMedical Center Boulevard, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1053, USA. mrocco@wakehealth.edu
Robert S Lockridge
Gerald J Beck
Paul W Eggers
Jennifer J Gassman
Tom Greene
Brett Larive
Christopher T Chan
Glenn M Chertow
Michael Copland
Christopher D Hoy
Robert M Lindsay
Nathan W Levin
Daniel B Ornt
Andreas Pierratos
Mary F Pipkin
Sanjay Rajagopalan
John B Stokes
Mark L Unruh
Robert A Star
Alan S Kliger
Frequent Hemodialysis Network (FHN) Trial Group
A Kliger
P Eggers
J Briggs
T Hostetter
A Narva
R Star
B Augustine
P Mohr
G Beck
Z Fu
J Gassman
T Greene
J Daugirdas
L Hunsicker
B Larive
M Li
J Mackrell
K Wiggins
S Sherer
B Weiss
S Rajagopalan
J Sanz
S Dellagrottaglie
M Kariisa
T Tran
J West
M Unruh
R Keene
J Schlarb
C Chan
M McGrath-Chong
R Frome
H Higgins
S Ke
O Mandaci
C Owens
C Snell
G Eknoyan
L Appel
A Cheung
A Derse
C Kramer
N Geller
R Grimm
L Henderson
S Prichard
E Roecker
M Rocco
B Miller
J Riley
R Schuessler
R Lockridge
M Pipkin
C Peterson
C Hoy
A Fensterer
D Steigerwald
J Stokes
D Somers
A Hilkin
K Lilli
W Wallace
B Franzwa
E Waterman
C Chan
M McGrath-Chong
M Copland
A Levin
L Sioson
E Cabezon
S Kwan
D Roger
R Lindsay
R Suri
J Champagne
R Bullas
A Garg
A Mazzorato
E Spanner
M Rocco
J Burkart
S Moossavi
V Mauck
T Kaufman
A Pierratos
W Chan
K Regozo
S Kwok

Funding

Inhibition Of Renal InjuryZIADK043403 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI STAR, ROBERT A · 2009 to 2025
$15.5M
Frequent Hemodialysis Network (FHN) - Nocturnal Clinical Core ConsortiumU01DK066480 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ROCCO, MICHAEL V · 2003 to 2010
$3.7M
NIDDK NIH HHS U01 DK066480
6 · The paper itself

Abstract

Prior small studies have shown multiple benefits of frequent nocturnal hemodialysis compared to conventional three times per week treatments. To study this further, we randomized 87 patients to three times per week conventional hemodialysis or to nocturnal hemodialysis six times per week, all with single-use high-flux dialyzers. The 45 patients in the frequent nocturnal arm had a 1.82-fold higher mean weekly stdKt/V(urea), a 1.74-fold higher average number of treatments per week, and a 2.45-fold higher average weekly treatment time than the 42 patients in the conventional arm. We did not find a significant effect of nocturnal hemodialysis for either of the two coprimary outcomes (death or left ventricular mass (measured by MRI) with a hazard ratio of 0.68, or of death or RAND Physical Health Composite with a hazard ratio of 0.91). Possible explanations for the left ventricular mass result include limited sample size and patient characteristics. Secondary outcomes included cognitive performance, self-reported depression, laboratory markers of nutrition, mineral metabolism and anemia, blood pressure and rates of hospitalization, and vascular access interventions. Patients in the nocturnal arm had improved control of hyperphosphatemia and hypertension, but no significant benefit among the other main secondary outcomes. There was a trend for increased vascular access events in the nocturnal arm. Thus, we were unable to demonstrate a definitive benefit of more frequent nocturnal hemodialysis for either coprimary outcome.

Indexed as

Hemodialysis, HomeAdultAgedEquipment DesignFemaleHumansHyperphosphatemiaHypertensionHypertrophy, Left VentricularKidney Failure, ChronicMagnetic Resonance ImagingMaleMiddle AgedNorth AmericaPatient ComplianceProportional Hazards Models

Identifiers

PMID21775973
PMCPMC3569086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.